NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 215 participants.
Also called NCT07018596
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 215 participants
- Sponsor
- Pulse Biosciences, Inc.
- Registry
-
NCT07018596
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Czechia
- Registry status
- Recruiting
Technical summary
Registry record NCT07018596. Allocation not applicable; no masking; primary purpose treatment. Start 2026-04-06 (actual); primary completion 2026-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System
- Acronym
- NANOPULSE-AF
- Condition
- Atrial Fibrillation Paroxysmal
- Condition
- Cardiac Ablation
- Condition
- Cardiac Arrhythmia
- Intervention (Device)
- CellFX nsPFA Cardiac Catheter System
- Lead sponsor
- Pulse Biosciences, Inc.
Record details
- Record id
cardio:ct-nct07018596- Content hash
03341638531e766d83c987642e528d69ab651960a25ec70a7e446b7b3041818a